Clinical Trials
23 trialsSelinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
University of Chicago
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Wake Forest University Health Sciences
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
University of Southern California
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
The Cleveland Clinic
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
National Cancer Institute (NCI)
AML-17
European Organisation for Research and Treatment of Cancer - EORTC
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
The Cleveland Clinic
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
Case Comprehensive Cancer Center
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Fred Hutchinson Cancer Center